Sandostatin Injection is available as: sterile 1-mL ampuls in 3 strengths, containing 50, mcg octreotide (as acetate), and sterile 5-mL multi-dose vials in 2. Sep 3, Octreotide Acetate (Sandostatin ®) – Intravenous (IV) Dilution. Octreotide (Sandostatin) is the longer acting synthetic analogue of the naturally In patients with cancer and inoperable bowel obstruction octreotide rapidly.

Author: Brazuru Mikinos
Country: Bulgaria
Language: English (Spanish)
Genre: Marketing
Published (Last): 2 February 2016
Pages: 359
PDF File Size: 17.11 Mb
ePub File Size: 2.25 Mb
ISBN: 820-1-91972-341-2
Downloads: 93386
Price: Free* [*Free Regsitration Required]
Uploader: Mirn

The frequency of gastrointestinal adverse events is known to decrease over time with continued treatment. Occurrence of gastrointestinal side effects may be reduced by avoiding meals around the time of Octreotide s. Treatment of TSH-secreting pituitary adenomas The dosage most generally effective is micrograms three times a day by s.

Breastfeeding It is unknown whether octreotide is excreted in human breast milk. Now you can find the tools you need to help manage your patients, all in one place! Step 11 Activate safety guard over the needle by either: Adverse drug reactions Octreotice 1 are ranked under heading of frequency, the most frequent first, using the following convention: Date of revision of the text.

Dosing & Administration

This non-specific tissue reaction appeared to be particular to rats. Diarrhoea, abdominal pain, nausea, constipation, flatulence. In cirrhotic patients with bleeding gastro-oesophageal varices.

Complications following pancreatic surgery For patients undergoing pancreatic surgery, the peri- and post-operative administration of Octreotide reduces the incidence of typical post-operative complications e.

The treatment effects of octreotide were prospectively observed in 21 patients and pooled with series of 37 published cases.

Dosage information for patients with specific tumors follows. Nutrition Octreotide may alter absorption of dietary fats in some patients.


Clinical improvement is usually accompanied by a reduction in plasma VIP levels, which may fall into the normal reference range.

Hypoglycaemia, impaired glucose tolerance, anorexia Uncommon: Cardiovascular related events Common cases of bradycardia have been reported. Special patient population Impaired renal function did doais affect the total exposure AUC to octreotide administered as s.

In carcinoid tumours, if there is no beneficial response within 1 week of treatment with Octreotide at the maximum tolerated dose, therapy should not be continued. Octreotide-potent inhibitor of GH, insulin, and glucagon secretion. It is not known whether octreotide has an effect on human fertility.

No causal relationship to octreotide is suspected for these cases. Although administration of Sandostatin often leads to an immediate reduction in plasma glucagon levels, this decrease is generally not maintained over a prolonged period of administration, despite continued symptomatic improvement. It is important to closely follow the mixing instructions included in the packaging. Cytoprotective and supportive care agents Pituitary disorders. Sandostatin is to be used in association with specific treatment such as endoscopic sclerotherapy.

Insulinomas Administration of Sandostatin produces a fall in circulating immunoreactive octroetide, which may, however, be of short duration about 2 hours.

Repeat moderate shaking for another 30 seconds if the powder is not completely suspended. Table 1 Adverse drug reactions reported in clinical studies Gastrointestinal disorders Very common: In a week toxicity study in rats, predominantly in males, dosiz were noted at the s. Dose adjustment of medicinal products such as beta blockers, calcium channel blockers, or agents to control fluid and electrolyte balance may be necessary when Sandostatin is administered concomitantly see section 4.

Patients on total parenteral doss TPN and octreotide should have periodic monitoring of zinc levels. The dose can be adjusted according to the responses of TSH and thyroid hormones.


The biochemical characteristic of these tumours is overproduction of vasoactive intestinal peptide VIP. Common cases of bradycardia have been reported. During the treatment of GEP endocrine tumours, there may be rare instances of sudden escape from symptomatic control by Octreotide with rapid recurrence of severe symptoms.

The amount of Octreotide bound to blood cells is negligible. Sample dilutions for continuous infusion: Hypoglycaemia, impaired glucose tolerance, anorexia. Since, following bleeding episodes from oesophageal varices, there is an increased risk for the development of insulin-dependent diabetes or for changes in insulin requirement in patients with pre-existing diabetes, an appropriate monitoring of blood glucose levels is mandatory.

Gallbladder and related events Octreotide inhibits secretion of cholecystokinin, resulting in reduced contractility of the gallbladder and an increased risk of sludge and stone formation. Known hypersensitivity to the active substance or dsois any of the excipients listed in section 6.

Sandostatin® LAR Depot Dosing & Administration | HCP

In these patients, the response was maintained throughout the duration of treatment up to 61 months, mean, Novartis Pharmaceuticals Corporation has updated the Privacy Policy for this website. While the precise mode of action of Sandostatin is not fully elucidated, it is postulated that Sandostatin reduces splanchnic blood flow through inhibition ictreotide vaso-active hormones e.

Maintenance doses have to be adjusted individually.